Table 4 Baseline clinical and imaging characteristics associated with macrotrabecular-massive subtype.
Variables | Available data (n) | All patients n = 212 | Patients with MTM n = 25 | Patients without MTM n = 187 | p |
|---|---|---|---|---|---|
Age > 65 years old | 212 | 125 (59) | 16 (64) | 109 (58) | 0.68 |
Male (%) | 212 | 168 (79) | 19 (76) | 149 (80) | 0.46 |
Histological cirrhosis (%) | 212 | 181 (85) | 18 (72) | 163 (87) | 0.06 |
Etiology of liver disease (%) | 212 | 0.7 | |||
Hepatitis B | 26 (12.3) | 2 (9) | 2 (8.3) | ||
Hepatitis C | 76 (35.8) | 6 (28) | 5 (20.8) | ||
Alcohol | 82 (38.7) | 11 (52) | 10 (41.6) | ||
NASH | 20 (9.4) | 1 (4.7) | 2 (8.3) | ||
Other | 8 (3.8) | 1 (4.7) | 5 (20.8) | ||
AFP level (ng/mL) | 203 | 64.3 | 99 ± 29 | 168 ± 103 | 0.42 |
Child–Pugh class B (%) | 208 | 15 (7) | 2 (8) | 13 (6) | 0.7 |
Solitary | 212 | 164 (77) | 22 (88) | 142 (76) | 0.21 |
Tumor size (cm) | 212 | 2.8 ± 1 | 3.2 ± 2,5 | 2,8 ± 1 | 0.18 |
BCLC stage B | 208 | 15 (7) | 2 (5) | 13 (7) | 0.7 |
Atypical pattern of tumor vascular enhancement | 212 | 28 (13) | 3 (9.5) | 2(9) | 0.64 |
Non-smooth tumor margin | 212 | 46 (21.7) | 8 (32) | 38 (20) | 0.19 |
Tumor capsule | 212 | 109 (51) | 16 (64) | 93(49) | 0.2 |
Peri-vascular location | 212 | 86 (40) | 12 (48) | 74 (65) | 0.5 |
Peritumoral vascular enhancement | 212 | 30 (16) | 9 (36) | 21 (11) | 0.003 |
Edmondson grade 1 or 2 | 212 | 146 (69) | 10 (40) | 136 (72) | 0.002 |
Biliary marker expression | 201 | 23 (11) | 4 (17) | 19 (10) | 0.3 |
